SIAMAB THERAPEUTICS, INC.

617-714-9773

90 Bridge Street Suite 100, Newton, MA 02458

SIAMAB NEWS

ANGEL-FUNDED SIAMAB COMPLETES $202 MILLION EXIT WITH LARGE COMMERCIAL-STAGE BIOPHARMA - TRANSACTION VALIDATES ANTI-TACA THERAPEUTIC APPROACH FOR TREATMENT OF SOLID TUMORS

August 19, 2019

SIAMAB THERAPEUTICS ANNOUNCES PUBLICATION IN PLOS ONE OF POSITIVE DATA FROM PRECLINICAL STUDIES OF ITS ST1 ANTIBODY THERAPEUTIC IN DEVELOPMENT FOR OVARIAN CANCER

July 27, 2018

SIAMAB THERAPEUTICS ANNOUNCES PUBLICATION OF NEW DATA ON ITS ST1 LEAD PROGRAM IN THE JOURNAL ONCOTARGET

May 1, 2018

SIAMAB THERAPEUTICS TO PRESENT NEW DATA ON ITS ST1 ANTIBODY THERAPEUTIC PROGRAM TARGETING TUMOR-ASSOCIATED STN AND STN+ MYELOID DERIVED SUPPRESSOR CELLS AT THE AACR ANNUAL MEETING 2018

April 4, 2018

SIAMAB THERAPEUTICS TO PRESENT NEW DATA ON ITS ST1 ANTIBODY THERAPEUTIC PROGRAM TARGETING TUMOR-ASSOCIATED STN AND MDSCS AT BIOTECH SHOWCASE™ 2018

January 3, 2018

SIAMAB FEATURED IN OVARIAN CANCER NEWS TODAY: SIAMAB'S ANTIBODY-DRUG CONJUGATES FOR OVARIAN CANCER SEEN TO SUCCEED IN ANIMAL MODELS

November 6, 2017

SIAMAB FEATURED IN BIOCENTURY INNOVATIONS FROM IDEA TO IND: SWEET SPECIFICITY

November 6, 2017

SIAMAB THERAPEUTICS PRESENTS NEW PRECLINICAL SAFETY DATA FOR ST1 ANTIBODY THERAPEUTICS PROGRAM AT THE 2017 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

October 30, 2017

SIAMAB THERAPEUTICS AND BOEHRINGER INGELHEIM ANNOUNCE STRATEGIC CANCER IMMUNOLOGY DISCOVERY COLLABORATION TO DEVELOP ANTIBODY THERAPEUTICS TARGETING MULTIPLE SOLID TUMORS

October 4, 2017

SIAMAB THERAPEUTICS PRESENTS NEW DATA AT AACR’S OVARIAN CANCER CONFERENCE DEMONSTRATING ITS ANTI-STN ANTIBODY THERAPEUTICS INHIBIT TUMOR GROWTH IN OVARIAN CANCER MODELS

October 3, 2017

SIAMAB THERAPEUTICS PRESENTED NEW DATA FOR ITS ANTI-STN ANTIBODY THERAPEUTICS SHOWING MYELOID-DERIVED SUPPRESSOR CELLS AS A PROMISING CANCER IMMUNOTHERAPY TARGET AT CAMBRIDGE HEALTHTECH INSTITUTE’S TARGETING TUMOR MYELOID CELLS CONFERENCE

September 29, 2017

SIAMAB THERAPEUTICS TO PRESENT AT THE 2017 BIO INTERNATIONAL CONVENTION

June 8, 2017

SIAMAB THERAPEUTICS PRESENTS NEW PRECLINICAL DATA FOR ITS NOVEL ANTI-STN ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND ANTI-STN BISPECIFIC ANTIBODIES AT THE AACR ANNUAL MEETING 2017

April 4, 2017

SIAMAB THERAPEUTICS TO PRESENT NEW PRECLINICAL DATA FOR ITS NOVEL ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2017

March 23, 2017

SIAMAB THERAPEUTICS ANNOUNCES PUBLICATION OF NEW PRECLINICAL DATA IN THE JOURNAL MABS DESCRIBING ITS NOVEL MONOCLONAL ANTIBODY APPROACH TO TARGETING THE TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN STN

March 8, 2017

SIAMAB THERAPEUTICS PRESENTS PROMISING PRECLINICAL DATA AT 2016 AACR OVARIAN CANCER RESEARCH SYMPOSIUM

September 13, 2016